Abstract: A label printer with a paper-cutting mechanism includes a force-applying assembly operatively coupled to a paper-cutting assembly. The force-applying assembly receives an applied force and drives the paper-cutting assembly to move. The paper-cutting assembly includes a blade assembly and a paper-pressing assembly operatively coupled together, and an elastic member disposed between the blade assembly and the paper-pressing assembly. The blade assembly is supported by the force-applying assembly, while the paper-pressing assembly moves vertically relative to the blade assembly. The front-back and left-right movements of the paper-pressing assembly are restricted by the blade assembly. The paper-pressing assembly includes a paper-pressing plate and a first positioning pin, with one end of the elastic member connected to the first positioning pin. The blade assembly includes a blade and a blade holder with a second positioning pin. The other end of the elastic member is connected to the second positioning pin.

Abstract: The present invention provides an optical imaging lens. The optical imaging lens comprises eight lens elements positioned in an order from an object side to an image side. Through controlling convex or concave shape of surfaces of the lens elements and satisfying at least one inequality, the optical imaging lens may shorten system length with a good imaging quality.

Abstract: The present invention provides an optical imaging lens. The optical imaging lens comprises seven lens elements positioned in an order from an object side to an image side. Through controlling the convex or concave shape of the surfaces of the lens elements, the optical imaging lens may shorten system length and enlarge field of view and aperture size.

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

Abstract: Lewis acidic metal-organic framework (MOF) materials comprising triflate-coordinated metal nodes are described. The materials can be used as heterogenous catalysts in a wide range of organic group transformations, including Diels-Alder reactions, epoxide-ring opening reactions, Friedel-Crafts acylation reactions and alkene hydroalkoxylation reactions. The MOFs can also be prepared with metallated organic bridging ligands to provide heterogenous catalysts for tandem reactions and/or prepared as composites with support particles for use in columns of continuous flow reactor systems. Methods of preparing and using the MOF materials and their composites are also described.

Abstract: The present invention provides an optical imaging lens. The optical imaging lens comprises eight lens elements positioned in an order from an object side to an image side. Through controlling convex or concave shape of surfaces of the lens elements and satisfying at least one inequality, the optical imaging lens may shorten system length with a good imaging quality.

Abstract: The present invention provides an optical imaging lens. The optical imaging lens comprises seven lens elements positioned in an order from an object side to an image side. Through controlling the convex or concave shape of the surfaces of the lens elements, the optical imaging lens may shorten system length and enlarge field of view and aperture size.

Abstract: Prodrugs that target the low-density lipoprotein receptor (LDLR) and that comprise acid and/or enzyme cleavable acetal- or oxybenzyloxy-linked carbonate or carbamate bonds are described. Also described are core-shell nanoparticles comprising metal-organic framework cores or nanoscale metal bisphosphate coordination polymer cores, and lipid coating layers containing the prodrugs. The nanoparticle core can optionally contain one or more hydrophilic chemotherapeutic agents. The prodrugs and nanoparticles can be used in methods of treating cancer. For instance, the presently disclosed nanoparticles can be used for the co-delivery of multiple chemotherapeutic agents in methods providing increased accumulation of chemotherapeutic agents to a tumor compared to delivery of mixtures of free chemotherapeutic agents.

Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.

Abstract: Methods of treating cancer comprising the use of combinations of a retinoid, e.g., all-trans retinoic acid (ATRA), and radiotherapy are described. The administration of a retinoid can enhance the effect of radiotherapy, including enhancing fractionated, low-dose radiotherapy. Use of the combination increases tumor necrosis factor alpha (TNF-?)- and inducible nitric oxide synthase (iNOS)-producing inflammatory macrophages in local (radiated) and distal (non-radiated) tumors. The methods can optionally further involve the use of checkpoint blockade immunotherapy.

Abstract: Metal-organic layers (MOLs) and metal-organic nanoplates (MOPs) comprising photosensitizers are described. The MOLs and MOPs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation. Optionally, the photo sensitizer or a derivative thereof can form a bridging ligand of the MOL or MOP. Also described are methods of using MOLs and MOPs in photodynamic therapy, X-ray induced photodynamic therapy (X-PDT), radiotherapy (RT), radiodynamic therapy, or in radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator.

Abstract: Modified metal-organic framework (MOFs) are described that have surfaces with enhanced ability to coordinatively bond to or electrostatically interact with therapeutic agents, such as nucleic acids and small molecules and proteins with phosphate or carboxylate groups. Methods of providing the modified MOFs are described that include replacing strongly coordinating metal oxo cluster capping groups with weakly coordinating capping groups and/or incorporating organic bridging ligands with electron-withdrawing groups. MOFs with surface attached therapeutic agents (e.g., immunotherapeutic agents) prepared from the modified MOFs are also described, along with methods of using the MOFs as to treat cancer, e.g., via radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator. Thus, the described methods can involve cancer immunotherapy and in situ cancer vaccination.

Abstract: The present invention provides an optical imaging lens. The optical imaging lens comprises seven lens elements positioned in an order from an object side to an image side. Through controlling the convex or concave shape of the surfaces of the lens elements, the optical imaging lens may shorten system length and enlarge field of view and aperture size.

Abstract: The present invention provides an optical imaging lens. The optical imaging lens comprises eight lens elements positioned in an order from an object side to an image side. Through controlling convex or concave shape of surfaces of the lens elements, the optical imaging lens may shorten system length with a good imaging quality.

Abstract: Surface hydroxyl groups on porous and nonporous metal oxides, such as silica gel and alumina, were metalated with catalyst precursors, such as complexes of earth abundant metals (e.g., Fe, Co, Cr, Ni, Cu, Mn and Mg). The metalated metal oxide catalysts provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of organic transformations. The catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

Abstract: An optical imaging lens may include a first, a second, a third, a fourth, a fifth and a sixth lens elements positioned in an order from an object side to an image side. The optical imaging lens may satisfy AAG/(T3+T6)?2.500, wherein a sum of five air gaps from the first lens element to the sixth lens element along the optical axis is represented by AAG, a thickness of the third lens element along the optical axis is represented by T3, and a thickness of the sixth lens element along the optical axis is represented by T6.

Abstract: An optical imaging lens includes a first lens element to a seventh lens element, and each lens element has an object-side surface and an image-side surface. The second lens element has negative refracting power, a periphery region of the object-side surface of the third lens element is concave, an optical axis region of the image-side surface of the third lens element is convex, the fifth lens element has positive refracting power, an optical axis region of the image-side surface of the fifth lens element is convex, an optical axis region of the image-side surface of the sixth lens element is concave, an optical axis region of the image-side surface of the seventh lens element is concave, a periphery region of the image-side surface of the seventh lens element is convex. The optical imaging lens satisfies the following conditions: D11t42/AAG37?1.700 and D11t31/G34?12.000.

Abstract: A lighting apparatus includes a light source, a detector and a driver. The light source includes a first set of LED modules and a second set of LED modules. The first set of LED modules and the second set of LED modules emit lights with different color temperatures. The detector is used for detecting an operation pattern corresponding to one of a plurality of operation modes. The operation pattern is transmitted from an operation on a wall switch electrically connected to the lighting apparatus. The driver generates a first current to the first set of LED modules and a second current to the second set of LED modules based on the operation mode associated with the detected operation pattern. The operation mode corresponding to both a corresponding luminance level and a corresponding color temperature at the same time.

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.